Q-omics provides the consensus-scored PARM1 profile across patient tissues and cancer cell-line models. PARM1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PARM1 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, PARM1 RNA expression shows 21,103 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where PARM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARM1 survival associations across molecular data types. PARM1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARM1 RNA expression–survival associations across cancer types. High PARM1 expression shows favorable associations in KIRC, SKCM, HNSC, COAD, LUAD and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PARM1 RNA expression.
This table summarizes PARM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PARM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARM1 shows lower tumor expression in KIRC, COAD, KICH, KIRP, THCA and LUSC. The KIRC box plot shows higher PARM1 RNA expression in normal versus tumor tissue (log2 FC = −1.545, t-test p < 0.001).
This table shows molecular features associated with PARM1 in patient tissues and cancer cell lines. In patient samples, PARM1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PARM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
